[{"Study ID":"ARGX-113-1501","Study Name":"N/A","Study Product":"ARGX-113 IV (Efgartigimod)","Indication":"Healthy Volunteers (HV)","Study Phase":"Phase I","Masking":"Double-blind","Enrolment (A/P)":"","Enrolment %":"","Last Achieved Milestone":"CSR","Last Achieved Milestones Long":"Final Clinical Study Report","Protocol Title":"A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Intravenous Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of ARGX-113 in Healthy Males and Female Subjects of Non-Child Bearing Potential","Protocol Title_1":1},{"Study ID":"ARGX-113-1602","Study Name":"N/A","Study Product":"ARGX-113 IV (Efgartigimod)","Indication":"Generalized Myasthenia Gravis (gMG)","Study Phase":"Phase II","Masking":"Double-blind","Enrolment (A/P)":"","Enrolment %":"","Last Achieved Milestone":"CSR","Last Achieved Milestones Long":"Final Clinical Study Report","Protocol Title":"A Randomized, Double-blind, Placebo-Controlled Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients with Myasthenia Gravis who have Generalized Muscle Weakness","Protocol Title_1":19},{"Study ID":"ARGX-113-1603","Study Name":"N/A","Study Product":"ARGX-113 IV (Efgartigimod)","Indication":"Primary Immune Thrombocytopenia (ITP)","Study Phase":"Phase II","Masking":"Double-blind","Enrolment (A/P)":"","Enrolment %":"","Last Achieved Milestone":"CSR","Last Achieved Milestones Long":"Final Clinical Study Report","Protocol Title":"A Randomized, Double-blind, Placebo-controlled, Phase II Study to Evaluate the Safety, Efficacy and Pharmacokinetics of ARGX-113 in Patients with Primary Immune Thrombocytopenia, followed by an Open-Label Treatment Period","Protocol Title_1":32},{"Study ID":"ARGX-113-1701","Study Name":"N/A","Study Product":"ARGX-113 IV (Efgartigimod)","Indication":"Pemphigus Vulgaris and Foliaceus (PV & PF)","Study Phase":"Phase II","Masking":"Open Label","Enrolment (A/P)":"","Enrolment %":"","Last Achieved Milestone":"CSR","Last Achieved Milestones Long":"Final Clinical Study Report","Protocol Title":"An Open-label, Non-controlled, Phase II Study to Evaluate the\r\nSafety, Pharmacodynamics, Pharmacokinetics, Efficacy and\r\nConditions of Use of ARGX-113 in Patients with Mild to\r\nModerate Pemphigus (Vulgaris or Foliaceus)","Protocol Title_1":17},{"Study ID":"ARGX-113-1702","Study Name":"N/A","Study Product":"ARGX-113 SC (Efgartigimod), ARGX-113 IV (Efgartigimod)","Indication":"Healthy Volunteers (HV)","Study Phase":"Phase I","Masking":"Open Label","Enrolment (A/P)":"","Enrolment %":"","Last Achieved Milestone":"CSR","Last Achieved Milestones Long":"Final Clinical Study Report","Protocol Title":"A Randomized, Open-label, Parallel Group Study to Compare the Pharmacokinetics, Pharmacodynamics and Safety and Tolerability of a Subcutaneous Formulation with an Intravenous Formulation of ARGX-113 in Healthy Male Subjects","Protocol Title_1":1},{"Study ID":"ARGX-113-1704","Study Name":"ADAPT","Study Product":"ARGX-113 IV (Efgartigimod)","Indication":"Generalized Myasthenia Gravis (gMG)","Study Phase":"Phase III","Masking":"Double-blind","Enrolment (A/P)":"","Enrolment %":"","Last Achieved Milestone":"CSR","Last Achieved Milestones Long":"Final Clinical Study Report","Protocol Title":"A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Trial to Evaluate the Efficacy, Safety and Tolerability of ARGX-113 in Patients with Myasthenia Gravis Having Generalized Muscle Weakness","Protocol Title_1":68},{"Study ID":"ARGX-113-1705","Study Name":"ADAPT+","Study Product":"ARGX-113 IV (Efgartigimod)","Indication":"Generalized Myasthenia Gravis (gMG)","Study Phase":"Phase III","Masking":"Open Label","Enrolment (A/P)":"","Enrolment %":"","Last Achieved Milestone":"CSR","Last Achieved Milestones Long":"Final Clinical Study Report","Protocol Title":"A Long-Term, Single-Arm, Open-Label, Multicenter, Phase 3 Follow-on Trial of ARGX-113-1704 to Evaluate the Safety and Tolerability of ARGX-113 in Patients With Myasthenia Gravis Having Generalized Muscle Weakness","Protocol Title_1":48},{"Study ID":"ARGX-113-1801","Study Name":"ADVANCE","Study Product":"ARGX-113 IV (Efgartigimod)","Indication":"Primary Immune Thrombocytopenia (ITP)","Study Phase":"Phase III","Masking":"Double-blind","Enrolment (A/P)":"132/156","Enrolment %":"85%","Last Achieved Milestone":"CSR","Last Achieved Milestones Long":"Final Clinical Study Report","Protocol Title":"A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Efgartigimod (ARGX-113) 10 mg/kg Intravenous in Adult Patients With Primary Immune Thrombocytopenia","Protocol Title_1":126},{"Study ID":"ARGX-113-1802","Study Name":"ADHERE","Study Product":"rHuPH20, ARGX-113 SC (Efgartigimod)","Indication":"Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)","Study Phase":"Phase II","Masking":"Open-label run-in and double-blind","Enrolment (A/P)":"322/292","Enrolment %":"110%","Last Achieved Milestone":"CSR","Last Achieved Milestones Long":"Final Clinical Study Report","Protocol Title":"A Phase 2 Trial to Investigate the Efficacy, Safety, and Tolerability of Efgartigimod PH20 SC in Adult Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)","Protocol Title_1":213},{"Study ID":"ARGX-113-1803","Study Name":"ADVANCE+","Study Product":"ARGX-113 IV (Efgartigimod)","Indication":"Primary Immune Thrombocytopenia (ITP)","Study Phase":"Phase III","Masking":"Open Label","Enrolment (A/P)":"101/105","Enrolment %":"96%","Last Achieved Milestone":"LSFV","Last Achieved Milestones Long":"Last Subject First Visit","Protocol Title":"A Phase 3, Multicenter, Open-label, Long-term Trial to Evaluate the Safety and Efficacy of Efgartigimod (ARGX-113) 10 mg/kg Intravenous in Adult Patients With Primary Immune Thrombocytopenia","Protocol Title_1":61},{"Study ID":"ARGX-113-1901","Study Name":"N/A","Study Product":"rHuPH20, ARGX-113 SC (Efgartigimod)","Indication":"Healthy Volunteers (HV)","Study Phase":"Phase I","Masking":"Open Label","Enrolment (A/P)":"","Enrolment %":"","Last Achieved Milestone":"CSR","Last Achieved Milestones Long":"Final Clinical Study Report","Protocol Title":"A Phase 1, Randomized, Open-label, Parallel-group Trial to Investigate the Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of Different Single Subcutaneous Dose Levels of Efgartigimod Co-administered with rHuPH20 in Healthy Adult Male Subjects","Protocol Title_1":1},{"Study ID":"ARGX-113-1902","Study Name":"ADHERE+","Study Product":"rHuPH20, ARGX-113 SC (Efgartigimod)","Indication":"Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)","Study Phase":"Phase II","Masking":"Open Label","Enrolment (A/P)":"229/229","Enrolment %":"100%","Last Achieved Milestone":"LSFV","Last Achieved Milestones Long":"Last Subject First Visit","Protocol Title":"Open-label Extension of the ARGX-113-1802 Trial to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)","Protocol Title_1":142},{"Study ID":"ARGX-113-1904","Study Name":"ADDRESS","Study Product":"rHuPH20, ARGX-113 SC (Efgartigimod)","Indication":"Pemphigus Vulgaris and Foliaceus (PV & PF)","Study Phase":"Phase III","Masking":"Double-blind","Enrolment (A/P)":"222/213","Enrolment %":"104%","Last Achieved Milestone":"CSR","Last Achieved Milestones Long":"Final Clinical Study Report","Protocol Title":"A Randomized, Double-Blinded, Placebo-Controlled Trial to Investigate the Efficacy, Safety, and Tolerability of Efgartigimod PH20 SC in Adult Patients With Pemphigus (Vulgaris or Foliaceus)","Protocol Title_1":136},{"Study ID":"ARGX-113-1905","Study Name":"ADDRESS+","Study Product":"rHuPH20, ARGX-113 SC (Efgartigimod)","Indication":"Pemphigus Vulgaris and Foliaceus (PV & PF)","Study Phase":"Phase III","Masking":"Open Label","Enrolment (A/P)":"183/183","Enrolment %":"100%","Last Achieved Milestone":"DBL","Last Achieved Milestones Long":"Database Lock","Protocol Title":"An Open-Label, Multicenter, Follow-up Trial of ARGX-113-1904 to Evaluate the Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Patients With Pemphigus (ADDRESS+)","Protocol Title_1":128},{"Study ID":"ARGX-113-1907","Study Name":"N/A","Study Product":"rHuPH20, ARGX-113 IV (Efgartigimod)","Indication":"Healthy Volunteers (HV)","Study Phase":"Phase I","Masking":"Open Label","Enrolment (A/P)":"","Enrolment %":"","Last Achieved Milestone":"CSR","Last Achieved Milestones Long":"Final Clinical Study Report","Protocol Title":"A Phase 1, Randomized, Open-Label, Parallel-Group Study to Compare the Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of Multiple Intravenous Infusions of Efgartigimod With Multiple Subcutaneous Injections of Efgartigimod PH20 SC in Healthy Subjects","Protocol Title_1":1},{"Study ID":"ARGX-113-2001","Study Name":"ADAPT SC","Study Product":"rHuPH20, ARGX-113 IV (Efgartigimod)","Indication":"Generalized Myasthenia Gravis (gMG)","Study Phase":"Phase III","Masking":"Open Label","Enrolment (A/P)":"111/76","Enrolment %":"146%","Last Achieved Milestone":"CSR","Last Achieved Milestones Long":"Final Clinical Study Report","Protocol Title":"A Phase 3, Randomized, Open-Label, Parallel-Group Study to Compare the Pharmacodynamics, Pharmacokinetics, Efficacy, Safety, Tolerability, and Immunogenicity of Multiple Subcutaneous Injections of Efgartigimod PH20 SC With Multiple Intravenous Infusions of Efgartigimod in Patients With Generalized Myasthenia Gravis","Protocol Title_1":51},{"Study ID":"ARGX-113-2002","Study Name":"ADAPT SC+","Study Product":"rHuPH20, ARGX-113 SC (Efgartigimod)","Indication":"Generalized Myasthenia Gravis (gMG)","Study Phase":"Phase III","Masking":"Open Label","Enrolment (A/P)":"184/159","Enrolment %":"116%","Last Achieved Milestone":"LSFV","Last Achieved Milestones Long":"Last Subject First Visit","Protocol Title":"A Long-Term, Single Arm, Open-Label, Multicenter, Phase 3 Study to Evaluate the Safety and Tolerability of Multiple Subcutaneous Injections of Efgartigimod PH20 SC in Patients With Generalized Myasthenia Gravis.","Protocol Title_1":47},{"Study ID":"ARGX-113-2003","Study Name":"ADAPT NXT","Study Product":"ARGX-113 IV (Efgartigimod)","Indication":"Generalized Myasthenia Gravis (gMG)","Study Phase":"Phase IIIb","Masking":"Open Label","Enrolment (A/P)":"69/72","Enrolment %":"96%","Last Achieved Milestone":"LSFV","Last Achieved Milestones Long":"Last Subject First Visit","Protocol Title":"A Phase 3b, Randomized, Open-Label, Parallel-Group Study to Evaluate Different Dosing Regimens of Intravenous Efgartigimod to Maximize and Maintain Clinical Benefit in Patients With Generalized Myasthenia Gravis","Protocol Title_1":41},{"Study ID":"ARGX-113-2004","Study Name":"ADVANCE SC","Study Product":"rHuPH20, ARGX-113 SC (Efgartigimod)","Indication":"Primary Immune Thrombocytopenia (ITP)","Study Phase":"Phase III","Masking":"Double-blind","Enrolment (A/P)":"63/53","Enrolment %":"119%","Last Achieved Milestone":"CSR","Last Achieved Milestones Long":"Final Clinical Study Report","Protocol Title":"A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Efficacy and the Safety of Efgartigimod (ARGX-113) PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia","Protocol Title_1":208},{"Study ID":"ARGX-113-2005","Study Name":"ADVANCE SC+","Study Product":"rHuPH20, ARGX-113 SC (Efgartigimod)","Indication":"Primary Immune Thrombocytopenia (ITP)","Study Phase":"Phase III","Masking":"Open Label","Enrolment (A/P)":"173/173","Enrolment %":"100%","Last Achieved Milestone":"LSFV","Last Achieved Milestones Long":"Last Subject First Visit","Protocol Title":"A Phase 3, Multicenter, Open-label, Long-term Trial to Evaluate the Safety and Efficacy of Efgartigimod (ARGX 113) PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia","Protocol Title_1":81},{"Study ID":"ARGX-113-2006","Study Name":"ADAPT JR","Study Product":"ARGX-113 IV (Efgartigimod)","Indication":"Generalized Myasthenia Gravis (gMG)","Study Phase":"Phase II/III","Masking":"Open Label","Enrolment (A/P)":"13/18","Enrolment %":"72%","Last Achieved Milestone":"FSFV","Last Achieved Milestones Long":"First Subject First Visit","Protocol Title":"Open-label uncontrolled trial to evaluate pharmacokinetics, pharmacodynamics, safety and activity of efgartigimod in children from 2 to less than 18 years of age with generalized myasthenia gravis","Protocol Title_1":25},{"Study ID":"ARGX-113-2007","Study Name":"ALKIVIA","Study Product":"rHuPH20, ARGX-113 SC (Efgartigimod)","Indication":"Idiopathic Inflammatory Myopathies (Myositis)","Study Phase":"Phase II/III","Masking":"Double-blind","Enrolment (A/P)":"132/240","Enrolment %":"55%","Last Achieved Milestone":"FSFV","Last Achieved Milestones Long":"First Subject First Visit","Protocol Title":"A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy","Protocol Title_1":216},{"Study ID":"ARGX-113-2008","Study Name":"ADAPT JR.+","Study Product":"ARGX-113 IV (Efgartigimod)","Indication":"Generalized Myasthenia Gravis (gMG)","Study Phase":"Phase II/III","Masking":"Open Label","Enrolment (A/P)":"10/12","Enrolment %":"83%","Last Achieved Milestone":"FSFV","Last Achieved Milestones Long":"First Subject First Visit","Protocol Title":"A Long-term, Single-Arm, Open-label, Multicenter, Follow-on Trial of ARGX-113-2006 to Evaluate Safety of Efgartigimod Administered Intravenously in Children With Generalized  Myasthenia Gravis","Protocol Title_1":25},{"Study ID":"ARGX-113-2009","Study Name":"BALLAD","Study Product":"rHuPH20, ARGX-113 SC (Efgartigimod)","Indication":"Bullous Pemphigoid (BP)","Study Phase":"Phase II/III","Masking":"Double-blind","Enrolment (A/P)":"98/165","Enrolment %":"59%","Last Achieved Milestone":"LSFV","Last Achieved Milestones Long":"Last Subject First Visit","Protocol Title":"A Phase 2/3, Randomized, Double-Blinded, Placebo Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid","Protocol Title_1":127},{"Study ID":"ARGX-113-2010","Study Name":"BALLAD +","Study Product":"rHuPH20, ARGX-113 SC (Efgartigimod)","Indication":"Bullous Pemphigoid (BP)","Study Phase":"Phase III","Masking":"Open Label","Enrolment (A/P)":"61/109","Enrolment %":"56%","Last Achieved Milestone":"FSFV","Last Achieved Milestones Long":"First Subject First Visit","Protocol Title":"An Open-label Extension Study of ARGX-113-2009 to Evaluate the Long term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid","Protocol Title_1":47},{"Study ID":"ARGX-113-2011","Study Name":"ALKIVIA+","Study Product":"rHuPH20, ARGX-113 SC (Efgartigimod)","Indication":"Idiopathic Inflammatory Myopathies (Myositis)","Study Phase":"Phase III","Masking":"Open Label","Enrolment (A/P)":"69/192","Enrolment %":"36%","Last Achieved Milestone":"FSFV","Last Achieved Milestones Long":"First Subject First Visit","Protocol Title":"A Phase 3, Single-Arm, Multicenter, Open-label Extension of Study ARGX-113-2007 to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy","Protocol Title_1":166},{"Study ID":"ARGX-113-2102","Study Name":"N/A","Study Product":"PNEUMOVAX 23, ARGX-113 IV (Efgartigimod)","Indication":"Healthy Volunteers (HV)","Study Phase":"Phase I","Masking":"Open Label","Enrolment (A/P)":"36/36","Enrolment %":"100%","Last Achieved Milestone":"CSR","Last Achieved Milestones Long":"Final Clinical Study Report","Protocol Title":"A Randomized, Open-label, Placebo-Controlled, Parallel-Group Study to Evaluate the Immune Response to the Polyvalent Pneumococcal Vaccine (PNEUMOVAX 23) in Healthy Participants Receiving Intravenous Efgartigimod or Placebo","Protocol Title_1":1},{"Study ID":"ARGX-113-2103","Study Name":"N/A","Study Product":"ARGX-113 IV (Efgartigimod)","Indication":"Healthy Volunteers (HV)","Study Phase":"Phase I","Masking":"Double-blind","Enrolment (A/P)":"","Enrolment %":"","Last Achieved Milestone":"CSR","Last Achieved Milestones Long":"Final Clinical Study Report","Protocol Title":"ZAI (ZL-1103-005) A randomized, Double-Blinded, Placebo-Controlled Phase 1 Study to Investigate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of an Intravenous Formulation of Efgartigimod in Healthy Chinese Adult Subjects","Protocol Title_1":1},{"Study ID":"ARGX-113-2104","Study Name":"N/A","Study Product":"ARGX-113 IV (Efgartigimod)","Indication":"Postural Orthostatic Tachycardia Syndrome (POTS)","Study Phase":"Phase II","Masking":"Double-blind","Enrolment (A/P)":"","Enrolment %":"","Last Achieved Milestone":"DBL","Last Achieved Milestones Long":"Database Lock","Protocol Title":"Quincy Model - A phase 2 randomized, double-blinded, placebo-controlled study to evaluate the efficacy and safety of efgartigimod IV in adult patients with post–COVID-19 postural orthostatic tachycardia syndrome (POTS)","Protocol Title_1":11},{"Study ID":"ARGX-113-2105","Study Name":"N/A","Study Product":"ARGX-113 IV (Efgartigimod)","Indication":"Postural Orthostatic Tachycardia Syndrome (POTS)","Study Phase":"Phase II","Masking":"Open Label","Enrolment (A/P)":"","Enrolment %":"","Last Achieved Milestone":"LSFV","Last Achieved Milestones Long":"Last Subject First Visit","Protocol Title":"Quincy Model - Open-Label Extension Study to Evaluate the Long term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) who Completed Study ARGX 113-2104","Protocol Title_1":9},{"Study ID":"ARGX-113-2106","Study Name":"N/A","Study Product":"ARGX-113 IV (Efgartigimod)","Indication":"Sjogren's Syndrome (SS)","Study Phase":"Phase II","Masking":"Double-blind","Enrolment (A/P)":"","Enrolment %":"","Last Achieved Milestone":"DBL","Last Achieved Milestones Long":"Database Lock","Protocol Title":"Quincy Model - A Phase 2, Randomized, Placebo-Controlled, Parallel-Group, Double-Blinded, Proof-of-Concept Study to Evaluate the Safety and Efficacy of Intravenous Efgartigimod in Adult Participants With Primary Sjögren’s Syndrome","Protocol Title_1":18},{"Study ID":"ARGX-113-2107","Study Name":"N/A","Study Product":"rHuPH20, ARGX-113 SC (Efgartigimod)","Indication":"Healthy Volunteers (HV)","Study Phase":"Phase I","Masking":"Double-blind","Enrolment (A/P)":"","Enrolment %":"","Last Achieved Milestone":"CSR","Last Achieved Milestones Long":"Final Clinical Study Report","Protocol Title":"ZAI (ZL-1103-006) A Randomized, Double-Blinded and Placebo-Controlled Phase 1 Study to Investigate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Efgartigimod SC Co-formulated with rHuPH20 in Healthy Chinese Adult Subjects","Protocol Title_1":1},{"Study ID":"ARGX-113-2201","Study Name":"N/A","Study Product":"ARGX-113 IV (Efgartigimod)","Indication":"Renally-impaired participants","Study Phase":"Phase I","Masking":"Open Label","Enrolment (A/P)":"33/32","Enrolment %":"103%","Last Achieved Milestone":"DBL","Last Achieved Milestones Long":"Database Lock","Protocol Title":"A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics of Efgartigimod IV 10mg/kg Single Dose Administered in Participants With Renal Impairment","Protocol Title_1":2},{"Study ID":"ARGX-113-2202","Study Name":"N/A","Study Product":"ARGX-113 IV (Efgartigimod)","Indication":"Lupus Nephritis (LN)","Study Phase":"Phase II","Masking":"Double-blind","Enrolment (A/P)":"47/72","Enrolment %":"65%","Last Achieved Milestone":"FSFV","Last Achieved Milestones Long":"First Subject First Visit","Protocol Title":"ZAI (ZL-1103-013 ) A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Study to Evaluate the Efficacy and Safety of Efgartigimod in Chinese Patients With Lupus Nephritis","Protocol Title_1":29},{"Study ID":"ARGX-113-2203","Study Name":"N/A","Study Product":"ARGX-113 IV (Efgartigimod)","Indication":"Primary Membranous Nephropathy (MN)","Study Phase":"Phase II","Masking":"Double-blind","Enrolment (A/P)":"47/72","Enrolment %":"65%","Last Achieved Milestone":"FSFV","Last Achieved Milestones Long":"First Subject First Visit","Protocol Title":"ZAI (ZL-1103-014) A Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Proof-of-Concept Study to Evaluate the Efficacy and Safety of Efgartigimod in Chinese Patients With Primary Membranous Nephropathy","Protocol Title_1":31},{"Study ID":"ARGX-113-2204","Study Name":"N/A","Study Product":"rHuPH20, ARGX-113 SC (Efgartigimod)","Indication":"Healthy Volunteers (HV)","Study Phase":"Phase I","Masking":"Open Label","Enrolment (A/P)":"120/120","Enrolment %":"100%","Last Achieved Milestone":"CSR","Last Achieved Milestones Long":"Final Clinical Study Report","Protocol Title":"A Phase 1, Randomized, Open-label, Parallel-Group, Single-Dose, Bioequivalence Study of Efgartigimod PH20 SC Administered via a Prefilled Syringe Versus a Viral-Syringe Presentation in Healthy Adults","Protocol Title_1":2},{"Study ID":"ARGX-113-2207","Study Name":"ADAPT JR SC","Study Product":"rHuPH20, ARGX-113 SC (Efgartigimod)","Indication":"Generalized Myasthenia Gravis (gMG)","Study Phase":"Phase III","Masking":"Open Label","Enrolment (A/P)":"","Enrolment %":"","Last Achieved Milestone":"FSA","Last Achieved Milestones Long":"First Site Activated","Protocol Title":"An Open-label, Uncontrolled Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Activity of Efgartigimod PH20 SC in Participants From 2 to Less Than 18 Years of Age With Generalized Myasthenia Gravis","Protocol Title_1":22},{"Study ID":"ARGX-113-2211","Study Name":"N/A","Study Product":"ARGX-113 IV (Efgartigimod)","Indication":"Sjogren's Syndrome (SS)","Study Phase":"Phase II","Masking":"Open Label","Enrolment (A/P)":"","Enrolment %":"","Last Achieved Milestone":"LSFV","Last Achieved Milestones Long":"Last Subject First Visit","Protocol Title":"Quincy Model - Open-Label Extension Study to Evaluate the Safety of Efgartigimod in Adult Patients with primary Sjogrens Syndrome (pSS) who complete qualifying efgartigimod pSS studies","Protocol Title_1":11},{"Study ID":"ARGX-113-2301","Study Name":"UplighTED","Study Product":"rHuPH20, ARGX-113 SC (Efgartigimod)","Indication":"Thyroid Eye Disease (TED)","Study Phase":"Phase III","Masking":"Double-blind","Enrolment (A/P)":"0/108","Enrolment %":"0%","Last Achieved Milestone":"FSA","Last Achieved Milestones Long":"First Site Activated","Protocol Title":"A Phase 3, Randomized, Double-masked, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Durability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC administered by prefilled syringe (PFS) in Adult Participants with active Thyroid Eye Disease","Protocol Title_1":75},{"Study ID":"ARGX-113-2302","Study Name":"shAMRock","Study Product":"rHuPH20, ARGX-113 SC (Efgartigimod)","Indication":"Antibody-Mediated Rejection (AMR)","Study Phase":"Phase II","Masking":"Double-blind","Enrolment (A/P)":"0/29","Enrolment %":"0%","Last Achieved Milestone":"PA","Last Achieved Milestones Long":"Protocol Approval","Protocol Title":"A Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Phase 2 Study to Evaluate the Safety, Tolerability, and Efficacy of Efgartigimod in Kidney Transplant Recipients With Antibody Mediated Rejection.","Protocol Title_1":20},{"Study ID":"ARGX-113-2303","Study Name":"N/A","Study Product":"rHuPH20, ARGX-113 SC (Efgartigimod)","Indication":"Healthy Volunteers (HV)","Study Phase":"Phase I","Masking":"Open Label","Enrolment (A/P)":"48/48","Enrolment %":"100%","Last Achieved Milestone":"CSR","Last Achieved Milestones Long":"Final Clinical Study Report","Protocol Title":"A Phase 1, Single-Center, Randomized, Open-Label, Crossover  Study in Healthy Adults to Assess the Feasibility of Different Speeds of Subcutaneous Injection for Efgartigimod PH20 SC","Protocol Title_1":1},{"Study ID":"ARGX-113-2308","Study Name":"ADAPT SERON","Study Product":"ARGX-113 IV (Efgartigimod)","Indication":"Generalized Myasthenia Gravis (gMG)","Study Phase":"Phase III","Masking":"Double-blind","Enrolment (A/P)":"4/115","Enrolment %":"3%","Last Achieved Milestone":"FSFV","Last Achieved Milestones Long":"First Subject First Visit","Protocol Title":"A randomized, double-blinded, placebo-controlled, phase 3, parallel group design study evaluating the efficacy and safety of efgartigimod IV in adult participants with acetylcholine receptor binding antibody (AChR-Ab) seronegative generalized myasthenia gravis (gMG).","Protocol Title_1":108},{"Study ID":"ARGX-113-2309","Study Name":"UplighTED","Study Product":"rHuPH20, ARGX-113 SC (Efgartigimod)","Indication":"Thyroid Eye Disease (TED)","Study Phase":"Phase III","Masking":"Double-blind","Enrolment (A/P)":"1/108","Enrolment %":"1%","Last Achieved Milestone":"FSFV","Last Achieved Milestones Long":"First Subject First Visit","Protocol Title":"A Phase 3, Randomized, Double-masked, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Durability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC administered by prefilled syringe (PFS) in Adult Participants with active Thyroid Eye Disease","Protocol Title_1":76},{"Study ID":"ARGX-113-2312","Study Name":"N/A","Study Product":"rHuPH20, ARGX-113 SC (Efgartigimod)","Indication":"Healthy Volunteers (HV)","Study Phase":"Phase I","Masking":"Open Label","Enrolment (A/P)":"72/72","Enrolment %":"100%","Last Achieved Milestone":"CSR","Last Achieved Milestones Long":"Final Clinical Study Report","Protocol Title":"A Phase 1, Open-label, Randomized, Single-Dose, Two-Period Cross-Over, Bioequivalence Study of Efgartigimod PH20 SC Administered via a Prefilled Syringe Versus a Vial + Syringe Presentation in Healthy Adults","Protocol Title_1":2},{"Study ID":"ARGX-113-2315","Study Name":"ADAPT Oculus","Study Product":"rHuPH20, ARGX-113 SC (Efgartigimod)","Indication":"Ocular Myasthenia Gravis (Ocular MG)","Study Phase":"Phase III","Masking":"Double-blind","Enrolment (A/P)":"0/124","Enrolment %":"0%","Last Achieved Milestone":"PA","Last Achieved Milestones Long":"Protocol Approval","Protocol Title":"A randomized, double-blinded, placebo-controlled, phase 3, parallel-group design study evaluating the efficacy and safety of efgartigimod PH20 SC administered by prefilled syringe in adult participants with ocular myasthenia gravis","Protocol Title_1":86},{"Study ID":"ARGX-113-2317","Study Name":"","Study Product":"rHuPH20, ARGX-113 SC (Efgartigimod)","Indication":"Systemic Sclerosis (SSc)","Study Phase":"Phase II","Masking":"Double-blind","Enrolment (A/P)":"","Enrolment %":"","Last Achieved Milestone":"PA","Last Achieved Milestones Long":"Protocol Approval","Protocol Title":"A Randomized, Double-Blinded, Placebo-Controlled, Phase 2, Parallel-Group Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Adult Participants With Systemic Sclerosis","Protocol Title_1":28},{"Study ID":"ARGX-117-1901","Study Name":"N/A","Study Product":"rHuPH20, ARGX-117 IV (Empasiprubart)","Indication":"Healthy Volunteers (HV)","Study Phase":"Phase I","Masking":"Double-blind","Enrolment (A/P)":"109/112","Enrolment %":"97%","Last Achieved Milestone":"CSR","Last Achieved Milestones Long":"Final Clinical Study Report","Protocol Title":"A First-in-Human, Randomized, Double-Blinded, Placebo-Controlled Trial in Healthy Subjects to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Single and Multiple Ascending Intravenous Dose Levels of ARGX 117 and Subcutaneous Dose Levels of ARGX-117 Co-Mixed With Recombinant Human Hyaluronidase PH20.","Protocol Title_1":1},{"Study ID":"ARGX-117-2002","Study Name":"ARDA","Study Product":"ARGX-117 IV (Empasiprubart)","Indication":"Multifocal Motor Neuropathy (MMN)","Study Phase":"Phase II","Masking":"Double-blind","Enrolment (A/P)":"54/48","Enrolment %":"113%","Last Achieved Milestone":"DBL","Last Achieved Milestones Long":"Database Lock","Protocol Title":"A Phase 2, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, Multi-Center Trial to Evaluate the Efficacy, Safety and Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of 2 Dose Regimens of ARGX-117 in Adults With Multifocal Motor Neuropathy.","Protocol Title_1":41},{"Study ID":"ARGX-117-2003","Study Name":"ARDA+","Study Product":"ARGX-117 IV (Empasiprubart)","Indication":"Multifocal Motor Neuropathy (MMN)","Study Phase":"Phase II","Masking":"Open-label and double-blind","Enrolment (A/P)":"51/52","Enrolment %":"98%","Last Achieved Milestone":"LSFV","Last Achieved Milestones Long":"Last Subject First Visit","Protocol Title":"An Open-label Long Term Extension of the ARGX-117-2002 trial to Evaluate the Long-Term Safety and Tolerability and Efficacy of ARGX-117 in Adults With Multifocal Motor Neuropathy","Protocol Title_1":28},{"Study ID":"ARGX-117-2201","Study Name":"VARVARA","Study Product":"ARGX-117 IV (Empasiprubart)","Indication":"Delayed Graft Function (DGF)","Study Phase":"Phase II","Masking":"Double-blind","Enrolment (A/P)":"15/102","Enrolment %":"15%","Last Achieved Milestone":"FSFV","Last Achieved Milestones Long":"First Subject First Visit","Protocol Title":"A Phase 2 Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study to Assess the Efficacy and Safety of ARGX-117 in Preventing Delayed Graft Function and Reducing the Risk of Allograft Failure in Recipients of a Renal Allograft From High-Risk, Deceased Donor Transplants","Protocol Title_1":48},{"Study ID":"ARGX-117-2202","Study Name":"IMMERSION","Study Product":"N/A - Non-Interventional Study","Indication":"Multifocal Motor Neuropathy (MMN)","Study Phase":"N/A","Masking":"N/A","Enrolment (A/P)":"142/150","Enrolment %":"95%","Last Achieved Milestone":"FSFV","Last Achieved Milestones Long":"First Subject First Visit","Protocol Title":"A Multicenter Prospective Longitudinal Study of Clinical Outcomes, Disease Course, Health-Related Quality of Life, and Health Care Resource Utilization in Adult Patients With Multifocal Motor Neuropathy","Protocol Title_1":124},{"Study ID":"ARGX-117-2301","Study Name":"empacific","Study Product":"ARGX-117 IV (Empasiprubart)","Indication":"Dermatomyositis","Study Phase":"Phase II","Masking":"Double-blind","Enrolment (A/P)":"0/25","Enrolment %":"0%","Last Achieved Milestone":"FSA","Last Achieved Milestones Long":"First Site Activated","Protocol Title":"A Phase 2, Randomized, Double-Blinded, Placebo-Controlled, \r\nMulticenter Study to Evaluate the Safety, Tolerability, and Efficacy \r\nof Empasiprubart in Adults With Dermatomyositis","Protocol Title_1":32},{"Study ID":"ARGX-117-2303","Study Name":"N/A","Study Product":"ARGX-117 SC (Empasiprubart)","Indication":"Healthy Volunteers (HV)","Study Phase":"Phase I","Masking":"Open Label","Enrolment (A/P)":"24/24","Enrolment %":"100%","Last Achieved Milestone":"LSFV","Last Achieved Milestones Long":"Last Subject First Visit","Protocol Title":"A Phase 1, Open-label, Randomized, Parallel-group Study to Assess the Absolute Bioavailability of Empasiprubart SC in Healthy Participants","Protocol Title_1":1},{"Study ID":"ARGX-119-2201","Study Name":"N/A","Study Product":"ARGX-119 IV","Indication":"Healthy Volunteers (HV)","Study Phase":"Phase I","Masking":"Double-blind","Enrolment (A/P)":"112/108","Enrolment %":"104%","Last Achieved Milestone":"LSLV","Last Achieved Milestones Long":"Last Subject Last Visit","Protocol Title":"A First-in-Human, Randomized, Double-Blind, Placebo-Controlled Trial in Healthy Subjects to Investigate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of Single and Multiple Ascending Intravenous Dose Levels of ARGX-119","Protocol Title_1":1},{"Study ID":"ARGX-119-2302","Study Name":"N/A","Study Product":"ARGX-119 IV","Indication":"DOK 7 Congenital Myasthenic Syndrome","Study Phase":"Phase Ib","Masking":"Double-blind","Enrolment (A/P)":"","Enrolment %":"","Last Achieved Milestone":"PA","Last Achieved Milestones Long":"Protocol Approval","Protocol Title":"A Phase 1b, Double-Blinded, Randomized, Placebo-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Efficacy of ARGX-119 in Adult Participants With DOK7 Congenital Myasthenic Syndromes","Protocol Title_1":11},{"Study ID":"ARGX-119-2303","Study Name":"ReALiSe","Study Product":"ARGX-119 IV","Indication":"Amyotrophic Lateral Sclerosis (ALS)","Study Phase":"Phase IIa","Masking":"Double-blind","Enrolment (A/P)":"0/63","Enrolment %":"0%","Last Achieved Milestone":"PA","Last Achieved Milestones Long":"Protocol Approval","Protocol Title":"A Phase 2a, Double-Blinded, Randomized, Placebo-Controlled, and Active-Treatment Extension Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of ARGX-119 in Participants With Amyotrophic Lateral Sclerosis","Protocol Title_1":9},{"Study ID":"ARGX-119-NIS-2301","Study Name":"CMS","Study Product":"N/A - Non-Interventional Study","Indication":"DOK 7 Congenital Myasthenic Syndrome","Study Phase":"N/A","Masking":"N/A","Enrolment (A/P)":"36/30","Enrolment %":"120%","Last Achieved Milestone":"FSFV","Last Achieved Milestones Long":"First Subject First Visit","Protocol Title":"Multicenter, Multinational Natural History Study in Participants with DOK7 Congenital Myasthenic Syndrome","Protocol Title_1":12}]